Search research articles
Contact Us
Filters
Showing results (21-30 of 114) with videos related to
Page
of 12
Sort By:
Cancer Immunology, Immunotherapy : CII
|
April 5, 2011
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma
Larry D Anderson, Danielle R Cook, Tori N Yamamoto, et al.
Acta Haematologica
|
May 8, 2024
Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Aimaz Afrough, Pearl Rajan Abraham, Laura Turer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene
Harris V Naina, Daniel Levitt, Madhuri Vusirikala, et al.
Journal of Neuroimmunology
|
October 6, 2012
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease
Doris Lambracht-Washington, Bao-xi Qu, Min Fu, et al.
Blood Cancer Journal
|
November 5, 2023
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
Rahul Banerjee, Bo Wang, Larry D Anderson, et al.
Cellular and Molecular Neurobiology
|
June 1, 2011
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation
Doris Lambracht-Washington, Bao-Xi Qu, Min Fu, et al.
Transplantation and Cellular Therapy
|
June 29, 2022
Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Miguel-Angel Perales, Larry D Anderson, Tania Jain, et al.
Transplantation and Cellular Therapy
|
November 1, 2023
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Larry D Anderson, Binod Dhakal, Tania Jain, et al.
Oncology and Therapy
|
June 28, 2026
IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, et al.
Frontiers in Cardiovascular Medicine
|
October 10, 2022
Cardiovascular disease and chimeric antigen receptor cellular therapy
Anjali Rao, Andrew Stewart, Mahmoud Eljalby, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 114) with videos related to
Sort By:
Page
of 12
Cancer Immunology, Immunotherapy : CII
|
April 5, 2011
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma
Larry D Anderson, Danielle R Cook, Tori N Yamamoto, et al.
Acta Haematologica
|
May 8, 2024
Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Aimaz Afrough, Pearl Rajan Abraham, Laura Turer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene
Harris V Naina, Daniel Levitt, Madhuri Vusirikala, et al.
Journal of Neuroimmunology
|
October 6, 2012
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease
Doris Lambracht-Washington, Bao-xi Qu, Min Fu, et al.
Blood Cancer Journal
|
November 5, 2023
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
Rahul Banerjee, Bo Wang, Larry D Anderson, et al.
Cellular and Molecular Neurobiology
|
June 1, 2011
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation
Doris Lambracht-Washington, Bao-Xi Qu, Min Fu, et al.
Transplantation and Cellular Therapy
|
June 29, 2022
Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Miguel-Angel Perales, Larry D Anderson, Tania Jain, et al.
Transplantation and Cellular Therapy
|
November 1, 2023
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Larry D Anderson, Binod Dhakal, Tania Jain, et al.
Oncology and Therapy
|
June 28, 2026
IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, et al.
Frontiers in Cardiovascular Medicine
|
October 10, 2022
Cardiovascular disease and chimeric antigen receptor cellular therapy
Anjali Rao, Andrew Stewart, Mahmoud Eljalby, et al.
Page
of 12